|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Thoratec's CEO Discusses Q3 2011 Results - Earnings Call Transcript
JDS Uniphase shares surge in late trades after the company beats Wall Street expectations for its fiscal first quarter.
Thoratec Corporation (Nasdaq:THOR) hit a new 52-week high Monday as it is currently trading at $37.56, above its previous 52-week high of $37.55 with 353,100 shares traded as of 2:26 p.m. ET. Average volume has been 864,100 shares over the past 30 days.
Thoratec Corporation (Nasdaq:THOR) hit a new 52-week high Friday as it is currently trading at $37, above its previous 52-week high of $36.98 with 560,484 shares traded as of 1:50 p.m. ET. Average volume has been 847,900 shares over the past 30 days.
These stocks are setting up to break out and trade higher from current levels.
Thoratec's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Shares of Thoratec Corporation (Nasdaq:THOR) were gapping up Monday morning with an open price 14.9% higher than Friday's closing price. The stock closed at $27.42 yesterday and opened today's trading at $31.51.
AT&T downgraded at UBS from Buy to Neutral. Jetblue downgraded at Soleil from Buy to Hold. Nokia upgraded at Morgan Keegan.
TheStreet presents its daily rundown of the winners and losers in the small-cap space
El Paso Electric is downgraded from Buy to Hold at Jefferies, which said the stock is already pricing in above-average earnings growth potential.
NEW YORK (TheStreet) -- Guests include Richard Soloway, CEO of Napco Security Technologies, Richard Ferri, author of "The Power of Passive Investing" and Gil Morales, managing director at MoKa Investors
These highly-rated large and mid-cap health care companies are growth plays with very strong sentiment among analysts.
To make money in stocks, follow broad growth trends, says Cabot Money Management's Dennis Wassung.
If a growth stock doesn't offer a dividend, you may have to take it yourself.
Through options expiration, wait for the market to prove itself rather than increasing exposure right at resistance.
Gregg Greenberg breaks down today's market action with guests Michael Gregory, portfolio manager for the Highland Capital Long/Short Fund, Ken Shreve, TheStreet's Market Movers portfolio manager and Ed Ferko, senior manager for Vanguard's College Savings Plan Group.
Analyst lowers Boston Scientific but upgrades 4 other medical device makers to 'Outperform'
Thoratec says 3Q profit surges on success of heart pump; guidance boosts shares
There defensive names are companies whose products sell no matter how bad the economy is.
ISTA Pharmaceuticals plunged following an FDA rejection, helping keep health stocks flat.
Aspreva and CryoLife advance after projecting strong first-quarter results.
Myriad Genetics rises on better-than-expected second-quarter results.
Thoratec falls as a weak outlook overshadows better-than-expected earnings.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.